Merck's Keytruda extends lung cancer survival in combination trial

(Reuters) - Merck & Co Inc's blockbuster drug Keytruda in combination with two chemotherapy drugs was successful as a first line treatment for lung cancer, results from a key late-stage study showed on Tuesday.